1-8 of 8
Reinhard von Roemeling
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Acute Myeloid Leukemia Patients with FLT3 Mutation

Eric S. Winer, Amit Verma, Stefanie Groepper, Katharina S. S. Götze, Yasmin Abaza, Christoph Schliemann, Gaurav S Choudhary, Wanying Zhao, Cole Gallagher, Reinhard von Roemeling, Daniel J. DeAngelo
Journal: Blood
Blood (2023) 142 (Supplement 1): 2924.
https://doi.org/10.1182/blood-2023-190007
Published: 2023
Journal Articles

Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

Christian Grommes, Han Tun, Allison C. Rosenthal, Matthew A Lunning, Radhakrishnan Ramchandren, Lucia Regales, Wanying Zhao, Maureen Lane, Catherine Wang, Reinhard von Roemeling, Iris Isufi, Lori A. Leslie, Grzegorz S. Nowakowski
Journal: Blood
Blood (2023) 142 (Supplement 1): 4497.
https://doi.org/10.1182/blood-2023-189746
Published: 2023
Journal Articles

Trial in Progress: A Phase 1b Single-Arm, Open-Label Study of Emavusertib (CA-4948) in Combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia Patients in Complete Response with Measurable Residual Disease

Adolfo De La Fuente Burguera, Claudio Cerchione, Sebastian Scholl, Jan Moritz Middeke, Gaurav S Choudhary, Reinhard von Roemeling, Uwe Platzbecker
Journal: Blood
Blood (2023) 142 (Supplement 1): 5975.
https://doi.org/10.1182/blood-2023-190125
Published: 2023
Journal Articles

Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib

Klaus H. Metzeler, Eric S. Winer, Uwe Platzbecker, Amit Verma, Daniel J. DeAngelo, Stefano R. Tarantolo, David A. Sallman, James Dugan, Stefanie Gröpper, Katharina S. Goetze, Chia-Cheng Li, Wanying Zhao, Maureen Lane, Reinhard von Roemeling, Samantha Carlisle, Anne Weigert, Matthias Böhme, Anne Sophie Kubasch, Guillermo Garcia-Manero
Journal: Blood
Blood (2022) 140 (Supplement 1): 9048–9049.
https://doi.org/10.1182/blood-2022-167477
Published: 2022
Journal Articles

A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies

Grzegorz S. Nowakowski, MD, Lori A. Leslie, MD, Erel Joffe, MD MSc, Allison C. Rosenthal, D.O., Matthew A. Lunning, DO, FACP, Krish Patel, MD, Monica Mead, MD BS, Daniel J. Landsburg, MD, Timothy S. Fenske, MD, Radhakrishnan Ramchandren, Praveen Ramakrishnan Geethakumari, MD MS, Alan Skarbnik, MD, Elizabeth Martinez, PhD DHSC, MSN, Christopher Lieberman, Reinhard von Roemeling, MD, Han W. Tun, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 49–50.
https://doi.org/10.1182/blood-2020-140884
Published: 2020
Journal Articles

A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Guillermo Garcia-Manero, MD, Uwe Platzbecker, Stefano R. Tarantolo, MD, Stefanie Gropper, Chetasi Talati, MD, Katharina S. Götze, James Dugan, MD, Eric S. Winer, MD, Elizabeth Martinez, PhD DHSC, MSN, Christopher Lieberman, Reinhard von Roemeling, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16.
https://doi.org/10.1182/blood-2020-140889
Published: 2020
Journal Articles

Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study

Grzegorz S. Nowakowski, MD, Lori A. Leslie, MD, Anas Younes, Allison C. Rosenthal, D.O., Matthew A. Lunning, DO, FACP, Krish Patel, MD, Daniel J. Landsburg, MD, Elizabeth Martinez, PhD DHSC, MSN, Reinhard von Roemeling, MD, Christopher Lieberman, Han W. Tun, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-140857
Published: 2020
Journal Articles

A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax in Patients with Relapsed/Refractory (R/R) Lymphoma

Anas Younes, MD, Connie Lee Batlevi, MD PhD, Jonathon B. Cohen, MDMS, Sven de Vos, MD PhD, Daniel J. Landsburg, MD, Zaw Win Myint, MD, Krish Patel, MD, Tycel J. Phillips, MD, Sonali M. Smith, MD, Jason R. Westin, MD, Anna W Ma, MS, Dena Grayson, MD PhD, Reinhard von Roemeling, MD, Stefan K. Barta, MD MRCP, MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 4104.
https://doi.org/10.1182/blood-2019-128857
Published: 2019